Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-12-12)Premium Content

Sarepta Therapeutics Inc New (SRPT)

2015-02-27@01:56:17 ET
Sarepta Therapeutics to Offer Company Overview at Upcoming Conferences (CLM)

2015-02-26@08:15:48 ET
8-K: Sarepta Therapeutics, Inc. (EDK)

2015-02-26@07:12:43 ET
10-K: SAREPTA THERAPEUTICS, INC. (EDG)

2015-02-26@07:00:16 ET
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments (BIZ)

2015-02-25@07:24:26 ET
Dengue Therapeutics Pipeline Review, H1 2015 - Analysis of 33 Companies with 66 Drug Profiles (MTO)

2015-02-24@08:30:03 ET
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences (BIZ)

2015-02-19@08:30:16 ET
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update on February 26, 2015 (BIZ)

2015-02-18@09:31:00 ET
Critical Alerts For JC Penney, Tile Shop, Sarepta Therapeutics, Goodrich Petroleum Corp. and bluebird bio Inc. Released By InvestorsObserver (PRN)

2015-02-17@12:46:31 ET
Tuesday's ETF Movers: XBI, GDXJ (MNV)

2015-02-04@08:30:59 ET
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences (BIZ)

2015-01-30@10:32:03 ET
INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Law Offices of Howard G. Smith (BIZ)

2015-01-29@10:03:31 ET
UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT (PMZ)

2015-01-26@18:40:44 ET
ALERT: Rosen Law Firm Reminds Sarepta Therapeutics Investors of Important February 9, 2015 Deadline in Class Action Seeking to Recover Investor Losses -- SRPT (PMZ)

2015-01-20@12:32:01 ET
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc. (BIZ)

2015-01-19@17:31:01 ET
Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com (PRW)

2015-01-19@05:14:33 ET
Sarepta announces encouraging data from Phase IIb DMD study (DTM)

2015-01-19@05:13:05 ET
Sarepta initiates dosing in Phase I/II Duchenne muscular dystrophy study (DTM)

2015-01-19@01:51:04 ET
Sarepta Therapeutics Marks First Patient Dosed in European Phase I/II Study (CLM)

2015-01-15@02:29:16 ET
Sarepta Therapeutics Publishes Data on Long-Term Outcomes from Phase IIb Study (CLM)